Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Social anxiety and specific phobias

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Phobic anxiety with immediate harm

Suicidal intent, dangerous escape from a feared situation, severe self-neglect, collapse or anaphylaxis during a real exposure, or abrupt physical symptoms inconsistent with the established anxiety pattern requires urgent care.

Action: Remove immediate environmental danger, use ABCDE and emergency treatment for objective physical illness, and assess suicide, exploitation and safeguarding. Do not force exposure during crisis; arrange a proportionate medical or mental-health handover and a later collaborative treatment plan.

Synopsis

Separate fear of scrutiny from fear of a circumscribed object or situation, assess avoidance and functional impact, and select disorder-specific CBT and exposure while using medication appropriately and safely.

  • Social anxiety disorder is persistent fear of social situations where scrutiny and negative evaluation are possible, with avoidance or intense endurance and meaningful impairment.
  • Specific phobia is disproportionate fear and avoidance tied to a particular object or situation, such as animals, heights, blood-injection-injury or flying.
  • Ask what outcome is feared: humiliation suggests social anxiety, inability to escape suggests agoraphobia, and harm intrinsic to a circumscribed cue suggests specific phobia.
  • For adult social anxiety, offer individual disorder-specific CBT based on the Clark and Wells or Heimberg model; do not routinely prefer group CBT over individual treatment.
  • For specific phobia, graded in-vivo exposure within CBT is central; build a hierarchy and repeat safe contact while reducing escape and safety behaviours.
  • If an adult with social anxiety declines CBT and chooses medicine, NICE recommends an SSRI, either escitalopram or sertraline, with early activation and suicide monitoring.
  • Medication is not the core treatment for a specific phobia and a sedative taken before every exposure can block learning and create dependence.

Key red flags

Suicidal thinking linked to humiliation, isolation, bullying or chronic restriction requires direct assessment of intent, means, recent actions and protective supports.

Fainting with injury, exertional symptoms, objective allergy, hypoxia or neurological change during a feared situation warrants physical assessment rather than automatic attribution to phobia.

Refusal of essential food, healthcare, education or safe housing because of fear can create immediate physical and safeguarding risk.

Marked suspiciousness, fixed beliefs about persecution, developmental communication differences or body-image preoccupation may require a different or additional formulation.

Investigation priorities

01
Situation and feared-outcome mapFirst step

Identify triggers, predictions, bodily sensations, attention, safety behaviours, avoidance and consequences.

Management branches

Social-anxiety CBTShift attention and test social predictions

An adult chooses the recommended individual psychological treatment for social anxiety.

  1. Develop a disorder-specific formulation covering self-image, self-focused attention, anticipatory worry, safety behaviours and post-event rumination.
  2. Use attention training, behavioural experiments, objective feedback and graduated exposure while dropping strategies that conceal or prevent disconfirmation.
  3. Consolidate learning across meaningful settings, address residual shame and plan independent practice and relapse responses over the structured course.

Key medicines

Sertraline oralFor licensed adult social anxiety disorder, give 25 mg by mouth once daily for one week, then 50 mg once daily; increase by 50 mg no more often than weekly to a maximum of 200 mg daily if required.Assess early agitation, akathisia, suicidal thinking, mania, bleeding, hyponatraemia, sexual dysfunction and serotonergic interactions; do not use tablets as a substitute for graded behavioural change and taper gradually when stopping.
Escitalopram oralFor licensed adult social anxiety disorder, give 10 mg by mouth once daily; according to response reduce to 5 mg or increase to a maximum of 20 mg once daily.Review QT prolongation risk, age and hepatic dose limits, hyponatraemia, bleeding, activation, suicide risk, sexual effects and interacting medicines; avoid abrupt cessation and review continued benefit regularly.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG159 social anxiety recommendationsAdult disorder-specific CBT, supported self-help, medication sequence and safety monitoring.
  • NHS facing your fears exposure guidanceStructured graded exposure and the role of avoidance in maintaining fear.
  • NHS phobias overviewCurrent UK patient information on phobia presentation and treatment routes.
  • Sertraline tablets summary of product characteristicsLicensed social-anxiety dosing, titration and medicine cautions.
  • Escitalopram tablets summary of product characteristicsLicensed social-anxiety dose range and safety modifiers.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom